These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 16605301)

  • 61. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes.
    Lucumi A; Robledo S; Gama V; Saravia NG
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1990-5. PubMed ID: 9687395
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
    Rodrigues ML; Costa RS; Souza CS; Foss NT; Roselino AM
    Rev Inst Med Trop Sao Paulo; 1999; 41(1):33-7. PubMed ID: 10436668
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
    Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
    Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis.
    Morais-Teixeira Ed; Carvalho AS; Costa JC; Duarte SL; Mendonça JS; Boechat N; Rabello A
    Mem Inst Oswaldo Cruz; 2008 Jun; 103(4):358-62. PubMed ID: 18660990
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gene expression analysis of antimony resistance in Leishmania tropica using quantitative real-time PCR focused on genes involved in trypanothione metabolism and drug transport.
    Mohebali M; Kazemirad E; Hajjaran H; Kazemirad E; Oshaghi MA; Raoofian R; Teimouri A
    Arch Dermatol Res; 2019 Jan; 311(1):9-17. PubMed ID: 30390113
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
    Gutiérrez J; Vallejo B; Barbosa H; Pinzón J; Delgado G
    Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):321-8. PubMed ID: 23473403
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
    Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
    Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Glucantime susceptibility of Leishmania promastigotes under variable growth conditions.
    Moreira ES; Soares RM; Petrillo-Peixoto Mde L
    Parasitol Res; 1995; 81(4):291-5. PubMed ID: 7624285
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
    Mohammadzadeh M; Behnaz F; Golshan Z
    J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines.
    Ferreira-Pinto KC; Miranda-Vilela AL; Anacleto C; Fernandes AP; Abdo MC; Petrillo-Peixoto ML; Moreira ES
    Can J Microbiol; 1996 Sep; 42(9):944-9. PubMed ID: 8864217
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of Correlation between the In Vitro Susceptibility of Field Isolates of
    Ghobakhloo N; Motazedian MH; Pourmohammadi B; Yousefi Z
    J Arthropod Borne Dis; 2017 Mar; 11(1):132-138. PubMed ID: 29026860
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of Leishmania major strains in Iran.
    Mahmoudzadeh-Niknam H; Ajdary S; Riazi-Rad F; Mirzadegan E; Rezaeian A; Khaze V; Djadid ND; Alimohammadian MH
    Trop Med Int Health; 2012 Nov; 17(11):1335-44. PubMed ID: 22947226
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I; Alavi A
    Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
    Jabini R; Jaafari MR; Vahdati Hasani F; Ghazizadeh F; Khamesipour A; Karimi G
    Drug Res (Stuttg); 2015 Mar; 65(3):119-24. PubMed ID: 24623031
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
    Khamesipour A; Mohammadi A; Jaafari M; Eskandari S; Tasbihi M; Javadi A; Afshari F; Mortazavi H; Firooz A
    East Mediterr Health J; 2022 Sep; 28(9):658-663. PubMed ID: 36205204
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.
    Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA
    Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epidemiological Aspects of Cutaneous Leishmaniasis during 2009-2016 in Kashan City, Central Iran.
    Moein D; Masoud D; Saeed M; Abbas D
    Korean J Parasitol; 2018 Feb; 56(1):21-24. PubMed ID: 29529846
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes.
    Moreira ES; Petrillo-Peixoto ML
    Braz J Med Biol Res; 1991; 24(5):459-69. PubMed ID: 1823261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.